Majority of children vaccinated against hepatitis B not at increased risk of MSSeptember 26, 2008ST. PAUL, Minn. - The majority of children vaccinated against hepatitis B are not at an increased risk of developing multiple sclerosis (MS), according to a study to be published in the October 8, 2008, online issue of Neurology®, the medical journal of the American Academy of Neurology. The study based in France involved 349 children with MS and 2,941 children without the disease. The children were all under the age of 16. A total of 24.4 percent of the children with MS were vaccinated for hepatitis B in the three years before the study, compared to 27.3 percent for the children without MS. Although the study found that hepatitis B vaccination does not generally increase the risk of multiple sclerosis, the children with MS were 1.74 times more likely to have received a certain type of hepatitis B vaccine, called Engerix B®. Those children with MS developed symptoms three or more years after the vaccine. The risk was only found for this specific type of hepatitis B vaccine and not found for all vaccines against hepatitis B. This association cannot be taken as confirmation that the vaccine caused MS. Further studies are needed to determine whether this is a causal relationship. American Academy of Neurology |
|||||||||||||||||||||
| Related Hepatitis Current Events and Hepatitis News Articles Toward explaining why hepatitis B hits men harder than women Scientists in China are reporting discovery of unusual liver proteins, found only in males, that may help explain the long-standing mystery of why the hepatitis B virus (HBV) sexually discriminates -- hitting men harder than women. Largest-ever database for liver proteins may lead to treatments for hepatitis Scientists at a group of 11 research centers in China are reporting for the first time assembly of the largest-ever collection of data about the proteins produced by genes in a single human organ. Mount Sinai finds those with more difficult to treat forms of HCV are half as likely to get treated A new study by Mount Sinai researchers has for the first time found that patients with more difficult to treat forms of hepatitis C are half as likely to initiate treatment for the disease, when compared to patients with hepatitis C that is easier to treat. Extending treatment after liver transplant may benefit patients with hepatitis C recurrence Extending hepatitis C treatment for liver transplant patients beyond current practice results in high rates of clearance of the hepatitis C virus from the blood, as well as a low rate of relapse, according to a Henry Ford Hospital study. Hepatitis B does not increase risk for pancreatic cancer A Henry Ford Hospital study found that hepatitis B does not increase the risk for pancreatic cancer - and that only age is a contributing factor. Governor recognizes stem cell research at Einstein Albert Einstein College of Medicine of Yeshiva University hosted a roundtable discussion on stem cell research with New York Governor David A. Paterson today. Liver cells grown from patients' skin cells Scientists at The Medical College of Wisconsin in Milwaukee have successfully produced liver cells from patients' skin cells opening the possibility of treating a wide range of diseases that affect liver function. Injury and hazards in home health care nursing are a growing concern Patients continue to enter home healthcare ''sicker and quicker," often with complex health problems that may require extensive nursing care. Medication effective for acute liver failure in early stages of disease The antidote for acute liver failure caused by acetaminophen poisoning also can treat acute liver failure due to most other causes if given before severe injury occurs, UT Southwestern Medical Center researchers and their colleagues at 21 other institutions have found. New aging studies improving vaccine efficacy for the elderly A new study from the Trudeau Institute in Saranac Lake, New York, demonstrates that immune system cells important for both pathogen resistance and vaccine efficacy live longer in older animals but because of this longevity acquire functional defects. More Hepatitis Current Events and Hepatitis News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||